Provided are the reactive topical skin protectant formulations including: water or moisture; plate-like inorganic particle powder; and one or more selected from the group consisting of a) liquid perfluoride, b) polyol, c) perfluorinated polymer powder, d) polysaccharides, e) liquid silicon-based material, and f) additives, and the reactive topical skin protectant formulations may provide an effect of safely protecting the skin from various lesions and risks occurring by liquid chemical agents or harmful toxic substances penetrating the human skin.

Provided are the reactive topical skin protectant formulations including: water or moisture; plate-like inorganic particle powder; and one or more selected from the group consisting of a) liquid perfluoride, b) polyol, c) perfluorinated polymer powder, d) polysaccharides, e) liquid silicon-based material, and f) additives, and the reactive topical skin protectant formulations may provide an effect of safely protecting the skin from various lesions and risks occurring by liquid chemical agents or harmful toxic substances penetrating the human skin.

The present disclosure relates to compounds having the following structure: ##STR00001##
or a dermatologically acceptable salt thereof, and cosmetic or dermopharmaceutical compositions comprising the same, and methods for using the compounds or compositions for treating, protecting, and/or improving the condition and/or aesthetic appearance of skin, for example, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, or improving the appearance of fine lines and/or or wrinkles of skin comprising application of the compounds or compositions disclosed.

The present disclosure relates to compounds having the following structure: ##STR00001##
or a dermatologically acceptable salt thereof, and cosmetic or dermopharmaceutical compositions comprising the same, and methods for using the compounds or compositions for treating, protecting, and/or improving the condition and/or aesthetic appearance of skin, for example, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, or improving the appearance of fine lines and/or or wrinkles of skin comprising application of the compounds or compositions disclosed.

Methods and compounds are disclosed for wound healing by modulating autophagy. A formulation for modulating autophagy comprises a first modulating compound (FAM) selected from compounds having the general structure (I): ##STR00001## wherein: L represents a linker selected from CC, (a tolan), CHCH (a stilbene, preferably trans); or CR.sub.aCR.sub.b a stilbene derivative; where R.sub.a and R.sub.b are independently H or phenyl optionally substituted with (R.sup.3).sub.p or (R.sup.4).sub.q; R.sup.1 to R.sup.4 are independent substituents at any available position of the phenyl rings, preferably at 3, 3, 4, 4, and/or 5, 5; and m, n, p, and q are independently 0, 1, 2, or 3 representing the number of substituents of the rings, respectively, but at least one of m or n must be 1. Each R.sup.1 to R.sup.2 is independently selected from substituents described herein, including but not limited to hydroxyl, alkoxy, halo, halomethyl and glycosides. The formulation may also include an auxiliary autophagy modulating compound (AAM) as described herein. The formulation may include a hydrogel formed by the compounds themselves or otherwise and may include salts and/or complexes.

Methods and compounds are disclosed for wound healing by modulating autophagy. A formulation for modulating autophagy comprises a first modulating compound (FAM) selected from compounds having the general structure (I): ##STR00001## wherein: L represents a linker selected from CC, (a tolan), CHCH (a stilbene, preferably trans); or CR.sub.aCR.sub.b a stilbene derivative; where R.sub.a and R.sub.b are independently H or phenyl optionally substituted with (R.sup.3).sub.p or (R.sup.4).sub.q; R.sup.1 to R.sup.4 are independent substituents at any available position of the phenyl rings, preferably at 3, 3, 4, 4, and/or 5, 5; and m, n, p, and q are independently 0, 1, 2, or 3 representing the number of substituents of the rings, respectively, but at least one of m or n must be 1. Each R.sup.1 to R.sup.2 is independently selected from substituents described herein, including but not limited to hydroxyl, alkoxy, halo, halomethyl and glycosides. The formulation may also include an auxiliary autophagy modulating compound (AAM) as described herein. The formulation may include a hydrogel formed by the compounds themselves or otherwise and may include salts and/or complexes.

Provided are compositions, preferably azeotrope or azeotrope-like compositions including 1,1,1,4,4,4-hexafluoro-2-butene and chlorotrifluoropropene, particularly 1-chloro-3,3,3-trifluoropropene (HCFO-1233zd), and uses thereof of the compositions. The composition may be a heat transfer composition. The composition may be a blowing agent composition. The composition may be a solvent composition. The composition may be a sprayable composition.

Provided are compositions, preferably azeotrope or azeotrope-like compositions including 1,1,1,4,4,4-hexafluoro-2-butene and chlorotrifluoropropene, particularly 1-chloro-3,3,3-trifluoropropene (HCFO-1233zd), and uses thereof of the compositions. The composition may be a heat transfer composition. The composition may be a blowing agent composition. The composition may be a solvent composition. The composition may be a sprayable composition.

The present invention is directed to a personal composition comprising a) a strobilurin; b) a 2-pyridinol-N-oxide material wherein the ratio of a:b is from about 10:1 to about 1:20; wherein there is a synergistic anti-inflammatory/cellular stress activity.

Biocompatible, bistable or multistable (P-Type) photochromic nanoparticles or microparticles that can be embedded in the skin using techniques such as those used to create a tattoo with tattoo ink. The color of the tattoo using the biocompatible bistable or multistable photochromic microparticles can be written, erased or changed, and re-written locally in the skin by irradiation with light of appropriate wavelengths. Some formulations with much higher sensitivity to UV light than visible light can also be used as short-term intradermal colorimetric UV dosimeters that can be reset and re-used on an hourly or daily basis. These particles can be uniform aggregates or polymers containing P-type photochromic dyes, microencapsulated or core-shell structures with cores containing P-type photochromic dyes, or solid particulate materials with P-type photochromic dyes adsorbed on the surface or within their pores.